Talon Marqibo’s Confirmatory Trial Plan May Need To Be Reworked

FDA advisory committee members express concern about the toxicity of Marqibo in the elderly patients expected to enroll in the Phase III confirmatory study for advanced acute lymphoblastic leukemia.